Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation

Clinical Rheumatology

Volumn 23, Issue 3, 2004, Pages 256-261

  Miesbach, W ^a   Scharrer, I ^a   Asherson, R A ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Myocardial infarction; Recurrent pulmonary thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; HEPARIN; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; PHENPROCOUMON; STEROID; WARFARIN;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BUDD CHIARI SYNDROME; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HEART FAILURE; HELLP SYNDROME; HUMAN; INTERNATIONAL STANDARD UNIT; LIVEDO RETICULARIS; LUNG EMBOLISM; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PLASMAPHERESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT DISEASE; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEMATOMA, SUBDURAL; HUMANS; INTERNATIONAL NORMALIZED RATIO; PHENPROCOUMON; PREGNANCY; RECURRENCE; THROMBOEMBOLISM;

EID: 3042524972     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-004-0864-0     Document Type: Article

References (45)

1. Wilson WA, Gharavi AE, Koike T et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309-1311
2. Shoenfeld Y (2003) Etiology and pathogenic mechanism of the anti-phospholipid syndrome unraveled. Trends Immunol 24: 2-4
3. Roubey RAS (1998) Mechanism of autoantibody-mediated thrombosis. Lupus 8:114-20 (suppl 2)
4. Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752-763
5. Petri M (2000) Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15:145-151
6. Cervera R, Piette JC, Font J et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019-1027
7. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185-1190
8. Mackie IJ, Donohoe S, Machin SJ (2000) Lupus anticoagulant measurement. In: Khamashta MA (ed) Hughes syndrome. Antiphospholipid syndrome. Springer, London, pp 214-225
9. Triplett DA, Stocker KF, Unger GA (1993) The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 70:925-931
10. Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the dilute Russell viper venome time for the diagnosis of lupus anticoagulants. Blood 68:869-874
11. Rosner E, Pauzner R, Lusky A, Modan M, Many A (1987) Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 57:144-147
12. Harris EN, Gharavi AE, Boey ML et al. (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211-1214
13. Koschmieder S, Miesbach W, Fauth F, Bojunga J, Scharrer I, Brodt HR (2003) Combined plasmapharesis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Blood Coag Fibrinol 14:395-399
14. Asherson RA, Cervera R, Piette JC et al. (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195-207
15. Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508-512
16. Triplett DA, Asherson RA (2000) Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Haematol 65:154-159
17. Piette JC, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y (2003) The catastrophic antiphospholipid syndrome - Asherson's syndrome. Ann Med Interne 154:196-196
18. Levine SR, Salowich-Palm L, Sawaya KL et al. (1997) IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28:1660-1665
19. Rosove MH, Brewer PMC (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117:303-308
20. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52:689-692
21. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993-997
22. Seligsohn U, Lubetsky A (2001) Genetic susceptibility to venous thrombosis. N Engl J Med 344:1222-1231
23. Walker ID, Greaves M, Preston FE (2001) Investigation and management of heritable thrombophilia. Br J Haematol 114:512-528
24. Ginsberg JS, Wells PS, Brill-Edwards P et al. (1995) Anti-phospholipid antibodies and venous thromboembolism. Blood 86:3685-3691
25. Levine SR, Brey RL, Tilles BC, the APASS Study Group et al (2002) aPL and Stroke Study (APASS). Lupus 11:559 [Abstract]
26. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group (1997) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857-865
27. Rai R, Cohen H, Dave M, Regan L (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. Br Med J 314:253-257
28. Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174:1584-1589
29. Malaviya AN, Mourou M (2000) Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)? Lupus 9:561-562
30. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP (2000) Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160:2042-2048
31. Alarcón-Segovia D, Boffa MC, Branch W et al. (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499-503
32. Meroni PL, Moia M, Derksen RHWM et al. (2003) Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 12:504-507
33. Brey RL, Chapman J, Levine SR et al. (2003) Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 12:508-513
34. Chapman J, Rand JH, Brey RL et al. (2003) Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 12:514-517
35. Lockshin M, Tenedios F, Petri M et al. (2003) Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12:518-523
36. Tincani A, Branch W, Levy RA et al. (2003) Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12:524-529
37. Asherson RA, Cervera R, de Groot PG et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530-534
38. Asherson RA, Shoenfeld Y (2000) The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry? J Rheumatol 27:12-14
39. Flamholz R, Tran T, Grad GI et al. (1999) Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta (2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apheresis 14:171-176
40. Moll S, Ortel TL (1997) Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127:177-185
41. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB (1983) A mechanism for the hypoprothrombinemia of the acquired hypoprothtrombinemia-lupus anticoagulant syndrome. Blood 61:684-692
42. Neuwelt CM, Daikh DI, Linfoot JA et al. (1997) Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum 40:1534-1539
43. Erkan D, Zhang HW, Shriky RC, Merrill JT (2002) Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 11:215-220
44. Al Sayegh FA, Ensworth S, Huang S, Stein HB, Klinkhoff AV (1997) Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 24:1716-1718
45. Shoenfeld Y (2003) Systemic antiphospholipid syndrome. Lupus 12:497-498